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Moise´s Go´mez-Mateu, Guadalupe Go´mez Melis
Background Conclusions from randomized clinical trials (RCT) rely primarily
on the primary endpoint (PE) chosen at the design stage of the study. There should
generally be only one PE which should be able to provide the most clinically rele-
vant and scientific evidence regarding the potential efficacy of the new treatment.
Therefore, it is of utmost importance to select it appropriately.
Composite endpoints, consisting of the union of several endpoints, are often
used as PE in RCT. Go´mez and Lagakos (2013) develop a statistical methodology
to evaluate the convenience of using a CE as opposed to one of its components.
Their strategy is based on the asymptotic relative efficiency (ARE), relating the
efficiency of using the logrank test based on the CE versus the efficiency based on one
of its components. This paper introduces the freeware online platform CompARE
that facilitates the study of the performance of different candidate endpoints which
could be used as PE at the design stage of a trial. CompARE, through an intuitive
interface, implements the novel ARE method.
Results CompARE is an exploratory tool that can be used for a variety of
purposes. First, to study how efficient might be a CE compared to one of its
components in the sense of requiring a smaller sample size for the same significance
level and power. Second, to compute the required sample size both for marginal
components and for CE, even when the proportionality of the hazards’ assumption
for CE does not hold. Third, to visualize the shape of the hazard ratio over time
allowing to check possible departures from constancy. Fourth, to provide other
graphical outputs such as the survival functions for each endpoint. By means of a
cardiovascular case study, we briefly illustrate the main capabilities of the platform.
Conclusion Our software helps trialists to make more informed decisions on
the PE when encountered with several candidate endpoints in a study. Results for
different parameter values are shown immediately through tables and plots with
a user-friendly graphic interface. Conclusions and recommendations are also pro-
vided in written form. CompARE is accessible at: https://cinna.upc.edu/compare.
Keywords: Asymptotic relative efficiency, CompARE, composite endpoint,
non-proportional hazards, sample size, web-based application.
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Background
Composite outcomes consist of the union of several outcomes and are fre-
quently used in randomized clinical trials (RCT). In time-to-event analysis,
composite endpoints (CE) refer to the elapsed time from randomization until
the earliest observation among its components. In oncology trials, for in-
stance, progression-free survival is defined as the time to disease progression
or death, whichever occurs first.
The decision on whether to use a CE versus a single component as the
primary endpoint (PE) is controversial. The advantages and drawbacks
regarding the use of CE have been extensively discussed in the literature
(Ferreira-Gonza´lez, 2007; Freemantle, 2007; Tomlinson, 2010)[1, 2, 3]. A
major controversy rely on the significance of the CE when it does not hold
for the main component. Some authors have proposed approaches that
combine the superiority of the CE with the non inferiority of the main rele-
vant component (Rauch and Kieser, 2013)[4]. However, multiplicity adjust-
ment procedures for multiple outcomes, and assumptions on the effect sizes
and correlations between components must be taken into account (Song,
2009)[5].
Go´mez and Lagakos (2013)[6] develop a statistical methodology in order
to evaluate the convenience of using a relevant endpoint (RE), for instance
cardiovascular death, versus a CE consisting of the union of the RE plus
another additional endpoint AE, such as hospitalization. Their strategy is
based on the value of the asymptotic relative efficiency (ARE), which relates
the efficiency of using the logrank test based on the time to the CE versus
the efficiency based on the time to the RE. This behaviour leads to the
following criterion: choose the CE whenever ARE > 1 and keep the RE as
the primary endpoint for the trial otherwise. The ARE can be interpreted
as the reciprocal ratio of the sample sizes required for the logrank test based
on RE and on CE to attain the same power at the same significance level
(Go´mez and Go´mez-Mateu, 2014)[7].
The ARE can be expressed in terms of a short number of parameters
that investigators can anticipate at the design stage of the trial as follows:
1. The event rates p
(0)
R , p
(0)
A of observing the RE and the AE, respectively,
in the control group, during the follow-up of the trial.
2. The relative treatment effects on the RE and the AE given by the
hazard ratios HRR and HRA, respectively, which we assume that
they are constant over time.
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3. The Spearman correlation coefficient ρ between the times to both RE
and AE components of the CE.
The ARE method is implemented for administrative censoring for a given
follow-up period, and uses Weibull marginal times for the RE and the AE
because of its flexibility, which allows decreasing, constant and increasing
hazards. Furthermore, we consider a Frank’s Archimedean survival copula
relationship between the marginal times to derive the joint distribution.
Further details and assumptions regarding the joint behaviour of the times
to the RE and AE can be found in Go´mez and Lagakos’ (2013) paper[6].
To the best of our knowledge, there is not a software tool to study the
efficiency of a composite endpoint versus its components, neither to compute
sample sizes for non-constant hazard ratios.
In the current article, we present the new online tool CompARE. This
software platform aids investigators the study of the behaviour of several
endpoints considered as the PE at the design stage of a trial. This is ac-
complished by implementing the aforementioned ARE method. CompARE
can be viewed as an exploratory tool since it allows to generate a variety of
scenarios depending on different parameter values. It helps to evaluate how
efficient might be a CE versus one of its components in terms of sample size
for a given significance level and power. It is also a computational resource
for trialists to calculate sample sizes, both for the CE and for its compo-
nents, even when the assumption of the proportionality of the hazards for
the CE does not hold. Graphical outputs permit to depict the distribution
of each endpoint and the hazard ratios of the CE over time, providing a
practical tool to visually check the proportionality of the hazards.
Users introduce the information needed in CompARE through intuitive
web-page forms, such as the list of candidate endpoints, together with the
anticipated parameter values. Results for different parameter settings are
shown immediately by means of tables, plots and in written form.
We remark that the development of a tool as CompARE has been im-
perative because of the complexity of the ARE expression. The reader is
referred to the Appendix for the explicit expression for the ARE values. All
the computations have been programmed in R[8]. Furthermore, users need
no knowledge of R, nor do they need to install it on their computers, making
CompARE a useful tool for trialists.
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The LIFE study. A Motivating example
Throughout the next pages we will use The Losartan Intervention For End-
point reduction in hypertension study (LIFE) trial (Dahlo¨f et al., 2002)[9]
as an aid to present how CompARE works together with its capabilities.
The LIFE study was conducted to test the efficacy of an antihypertensive
treatment (Losartan) in patients with hypertension. The primary composite
endpoint was composed by the union of cardiovascular death, myocardial
infarction and stroke. While cardiovascular death and myocardial infarction
(CV death + MI) are considered the most clinically important components
(Sankoh et al., 2014)[10], and we refer to them as the relevant endpoint RE,
stroke acts as the additional endpoint AE (see Figure 1).
RELEVANT 
ENDPOINT
CV death
Myocardial infarction
ADDITIONAL 
ENDPOINT
Stroke
COMPOSITE  ENDPOINT
Figure 1: Pictorial representation of the composite endpoint and its components based on the
LIFE trial. CV stands for cardiovascular.
In this study, significant results using the time to the CE were achieved,
mainly due to the significance of the less important outcome, i.e. stroke.
The main question that our approach tries to answer is under which circum-
stances the inclusion of only the most important outcomes CV death + MI
would have been recommended as the primary endpoint. This illustration
brings to light the need for a practical tool for trialists based on the pre-
viously described methodology in order to know in which specific cases the
use of the RE alone or the use of CE is recommended in terms of efficiency,
as we detail in the next sections.
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Implementation
Tiki: software underneath CompARE
The web-based platform CompARE is built under the free software Tightly
Integrated Knowledge Infrastructure (Tiki Wiki CMS/Goupware)[11]. Free
and open-source software is widely used and is commonly developed with
volunteer computer programmers, guaranteeing that every user has equal
rights of access. It allows any programmer to study the source code, mod-
ify it, and share it (FSF)[12]. Moreover, online graphic interfaces leads to
collaboration synergies between partners from different areas such as com-
puting, biology or statistics.
We chose Tiki because the majority of other interface web programs
that include the use of R routines present problems in the short or medium
term (de Pedro and Sa´nchez, 2010)[13]. Moreover, Tiki is safe and updated
periodically by their community members, who add new features, fix bugs
and patch security holes. It is constantly maintained under the license LGPL
(Lesser General Public License). Repositories are used for the version control
system.
Other remarkable features of Tiki are the use of web-standard codes such
as HTML, PHP and javascript. Due to its flexibility, different applications
can be included through the use of plugins (Sapir, 2010)[14]. By means of
the pluginR[15], developed by De Pedro and Sa´nchez (2010)[13], it is possible
to execute the ARE method programmed with R[8] in CompARE (see the
scheme in Figure 2). We highlight that it is not necessary to install R locally
in a computer to run CompARE, nor is knowledge of R required.
Input information
(HTML forms)
Information processed
on the server
Execution of R code
(plugin R)
Results shown on
the Web
USER
Web interface
Internal results
saved in trackers
https://cinna.upc.edu/compare
Figure 2: General scheme of CompARE.
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CompARE step by step
Access and registration
You can access CompARE by means of any standard web browser such
as Mozilla Firefox, Internet Explorer or Google Chrome by clicking on the
following link: https://cinna.upc.edu/compare.
Only a quick registration is needed from the main web page. The system
asks you for a username and a password, which will be used to enter the ap-
plication under your own session. For security reasons, an e-mail is required.
You will have to accept the registration from your own e-mail. In order to
avoid spam registrations, you need to correctly introduce a captcha code
(Completely Automated Public Turing test to tell Computers and Humans
Apart). The web administrator accepts the registration as a final step.
Running CompARE. Example from the LIFE study
In this section we show the basic capabilities of CompARE by means of the
LIFE study that has been introduced in the Background. Advanced options
are described afterwards in another section. We assume that we have a set
of candidate endpoints together with a range of anticipated values for the
event probabilities and hazard ratios for the treatment effect.
Following the LIFE study data, we introduce the corresponding param-
eter values by means of an input grid, programed in Tiki as an entry form
(see Figure 3):
1. In the first column, we provide the name of each endpoint. We indicate
whether each endpoint is terminating (i.e., when the occurrence of
it precludes the observation of other endpoints). In our example, it
corresponds to CV death. Place the cursor over each header as an aid
for getting a quick definition of each concept.
2. We specify the expected probabilities of observing the event in the con-
trol group during the follow-up period. By default, when the relevant
or the additional endpoints consist of several components, CompARE
will use their maximum probability to calculate the ARE values (see
advanced options to choose other values). In our example, the RE is a
combination of CV death + myocardial infarction, with a frequency of
observation in the control group of 5%. The corresponding probability
for stroke is 7%.
3. We indicate the anticipated treatment effects in terms of the hazard
ratios between groups. By default, when the relevant or the additional
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endpoints consist of several components, CompARE will use the av-
erage hazard ratio to calculate the ARE values. We assume a hazard
ratio of the RE and stroke of 0.825 and 0.75, respectively.
4. We select whether the endpoint is a component of the relevant or the
additional endpoint.
5. In the last column, we select those candidates that form the composite
endpoint.
6. At the bottom, one can click on ”Remove executions history” to delete
previous analyses that may have been done before.
7. The ”Run” button executes the process.
By default, exponential distributions for the marginal times with mod-
erate correlations are assumed.
Figure 3: Input grid of information for each endpoint of the trial.
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Results
Once the program executes the computations, an output screen is shown,
which is divided into the following five tags: results, other scenarios, graph-
ical outputs, recorded results and sample size:
• Results: In this tag, a table specifies the parameter information set
by the user together with the exact value of ARE (see Figure 4). In
our example, the ARE value is 3.49. Note that in this case, the use of
the composite endpoint is clearly advisable, since the ARE is higher
than 1. That is, we would need a more than 3 times larger sample
size if we do not include stroke in the primary endpoint. A paragraph
below the table shows a detailed recommendation written in text.
• Other scenarios: Several scenarios depending on different correla-
tions and hazard ratios for stroke are detailed in a table (See Figure
5).
• Graphical outputs: A plot with survival distributions and hazard
ratios is shown at the bottom and the results from the previous tag are
shown graphically at the top (see Figure 6). Note that in the LIFE
study, the decision remains the same irrespective of the correlation.
However, if the expected hazard ratio for stroke would have been 0.9
instead of 0.75 (i.e., a smaller expected effect on the AE), the use of
CV death + MI would have been recommended as primary endpoint if
furthermore the two marginal times were strongly correlated (Go´mez
and Go´mez-Mateu (2016)[16]).
• Recorded results: In this tag, the user can see a table which sum-
marizes the results performed in previous analyses (See Figure 7).
• Sample size: Given a significance level of 5% and a statistical power
of 80%, the required sample size using CV death + MI is 14,617 pa-
tients (see Figure 8). If we add stroke to the PE, the required sample
size shrinks to 4,190. In the next subsection, we discuss the required
sample size for a variety of scenarios based on different anticipated
parameter values.
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Figure 4: Summary of results in CompARE.
Figure 5: Numerical results for different scenarios.
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Figure 6: Graphical results in CompARE combining different parameter values. The ”end of
study” time point corresponds to the follow-up period of the clinical trial.
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5Figure 7: History of previous computations.
Figure 8: Required sample size computations.
12
Sample size
We briefly introduce the sample size formulae implemented in CompARE
and use the LIFE trial to illustrate it. The main original feature is that the
sample size of the CE, even when the hazards are not proportional, can be
calculated based on the ARE values.
Sample size for the relevant endpoint
For time-to-event endpoints, the power of the test depends on the number of
events rather than on the sample size. Based on the asymptotic behaviour
of the logrank statistic, Schoenfeld’s formula (1981)[17] for the required
number of events eR (one-tailed test) is as follows:
eR =
(zα + zβ)
2
(ln(HRR))2Π(1−Π) ,
where zα and zβ are the standard normal quantiles corresponding to the left
tail probability for an α-significance level and a β-type II error, respectively.
Π is the proportion of patients allocated to the control group. The sample
size nR is as follows[18]:
nR =
eR
[p
(0)
R Π + p
(1)
R (1−Π)](1−W )
,
where p
(0)
R , p
(1)
R are the probability of observing the relevant endpoint in the
control and treatment group, respectively, for a fixed follow-up period. W
is the anticipated withdrawal proportion due to loss to follow-up. For equal
allocation between groups Π = 1/2, and without loss to follow-up W = 0,
the total number of required patients nR is given by:
nR =
2eR
p
(0)
R + p
(1)
R
. (1)
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Sample size for the composite endpoint
In Go´mez and Go´mez-Mateu [7], it is shown that the asymptotic relative
efficiency ARE of the logrank statistic for the CE versus the logrank statistic
for the RE can be interpreted, for a given significance level α and power
(1−β), as the ratio of the required sample sizes for the relevant endpoint (nR)
and for the composite endpoint (n∗); that is, ARE = nR/n∗. It follows that
for marginal and constant hazard ratio HRR and under the other anticipated
parameters needed to compute the ARE and described in the Background
section, the required number of patients if using the CE is given by:
n∗ =
nR
ARE
. (2)
Note that nR can be computed from (1). We address the reader to the
Appendix for the specific expression of the ARE.
Whenever the hazard ratio of the CE, HR∗(t), is approximately con-
stant, one could straightforwardly use Schoenfeld’s formulas to calculate
the sample size n∗. If the HR∗(t) is not constant, which usually occurs
in practice (Go´mez-Mateu, 2016)[19] (see Figure 9), CompARE computes
the sample size depending on different parameter values, based on the ARE
approach by means of the aforementioned formulas.
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Figure 9: Marginal hazard ratios HRR = 0.75, HRA = 0.9 for the relevant (RE) and additional
endpoint (AE), respectively, and hazard ratio HR∗ for the CE over time. We fix the probabilities
p
(0)
R = 0.05, p
(0)
A = 0.04 of observing the RE and the AE in the control group, respectively, with
constant hazards for the time to the RE and the AE, with null correlation (ρ = 0) (left), and
increasing hazards for the time to the AE with hight correlation (ρ = 0.9) (right).
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Sample size example from the LIFE study
We illustrate the required sample size for the CE (CV death + myocardial
infarction + stroke) in the LIFE trial depending on several parameter values.
We are using the parameter values of this study, namely the probability
p
(0)
R = 0.05 of observing the relevant endpoint RE (CV death + myocardial
infarction) in the control group (Atenolol), and the hazard ratio HRR = 0.82
for the RE. The probability p
(0)
A of observing the additional endpoint AE
(stroke) in the control group and the hazard ratio HRA for the AE are
0.07 and 0.75, respectively. All the computations assume a significance level
α = 0.05 and a statistical power (1− β) equal to 80%.
The required sample size, nR, for CV death + MI using formula (1) is
equal to 14,617 patients. The required sample size n∗ following equation
(2) would be 5150, 4190 and 3831 for high (ρ = 0.9), moderate (ρ = 0.5)
or low correlation (ρ = 0.15) between the times to (CV death + MI) and
stroke, respectively (see Table 1). However, if we approximate HR∗(t) by
the constant average between HRR and HRA, that is HR∗ = 0.79, the
sample sizes n′∗ according to the above correlations are 4572, 4213 and 4119,
respectively. This shows the relevance of taking into account the degree of
association as well as the hazard ratio values for the computation of the
sample size.
Note that when the relationship between CV death + MI and stroke is
weak (ρ = 0.15), the required number of patients n∗ using the ARE method
is 3831, while if we assume constant hazard ratio (HR) it would be 4119
patients. In contrast, whenever we have strong correlations (ρ = 0.9), the
sample size n∗ using the ARE method is 5150, while the constant HR would
imply a smaller sample size (n′∗ = 4572 < n∗ = 5150).
Table 1: Sample sizes nR, n∗ and n′∗ for the relevant endpoint RE, composite endpoint CE with
ARE, and for CE approximating the hazard ratio HR∗ = 0.79 by the average between the marginal
hazard ratios HRR = 0.82 and HRA = 0.75, respectively. The probabilities of observing the RE
and AE in treatment group p
(1)
R = 0.04 and p
(1)
A (which varies with ρ), respectively. p
(0)
∗ and p
(1)
∗
stand for the probability of observing the CE in the control and treatment group, respectively.
nR ARE n∗ n′∗ Correlation ρ p
(0)
∗ p
(1)
∗
14617 3.82 3831 4119 0.15 0.12 0.09
14617 3.49 4190 4213 0.5 0.11 0.09
14617 2.84 5150 4572 0.9 0.10 0.08
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Advanced options in CompARE
CompARE is extended to accommodate the comparison of different sce-
narios coming from a combination of different parameter values, distinct
than the given by default, that could represent other realistic situations for
the design of a clinical trial. First, the user can choose different marginal
laws for the time to each endpoint as well as different degrees of correla-
tion and different copulas. Second, CompARE is also extended to quantify
specific values for the combined probability and hazard ratios whenever it
comes from a combination of several components. When the user cannot
anticipate some of the needed parameters, CompARE provides a range of
plausible values.
Marginal distributions
We have extended CompARE to allow Weibull distributions. The density
and survival functions for each group j (j = 0, 1) used in CompARE are
parametrized as follows:
f (j)(t) =
β
(b(j))β
tβ−1e(−(t/b
(j))β)
S(j)(t) = e(−(t/b
(j))β),
where the shape parameter β for each group are assumed equal so that
constant hazard ratios’ assumption holds, and the scale parameters b(j) are
derived automatically taking into account all the anticipated parameter val-
ues.
From the drop-down menu in the advanced features box, the user can
choose between the following options (see Figure 3, bottom):
• Weibull distribution with decreasing hazard rate (β = 0.5),
• Weibull with constant hazard rate (β = 1) (exponential distribution),
• Weibull distribution with increasing hazard rate (β = 2).
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Correlation
As we have seen previously in our example, the correlation might play a
crucial role. Trialist might need to compare the efficiency of one endpoint
over the other in terms of the strength of the association between the times
to the relevant endpoint and the additional endpoint. Therefore, CompARE
incorporates the possibility to change the Spearman’s correlation values (see
Figure 3, bottom).
Copulas
An additional feature of CompARE is the possibility to change the cop-
ula used to build the bivariate distribution between the marginal times (see
Figure 10). In this sense, although the values of ARE might not be exactly
the same depending on the chosen copula, it has been proved that the con-
cordance in the decision on the primary endpoint is markedly high in the
majority of cases (Plana-Ripoll and Go´mez, 2015)[20].
Figure 10: Menu indicating different choices of copulas.
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Combined HR and probabilities
CompARE is also extended to accommodate the computation of combined
probabilities and combined hazard ratios based on the marginal components.
By default, CompARE uses the maximum probability and the average haz-
ard ratio to calculate the ARE values. Alternatively, CompARE proposes
a range of plausible values of the corresponding combined probability and
combined hazard ratio (for the latter case, only implemented for two compo-
nents so far). Based on this range of values, the user can introduce a specific
value for the combined parameters by means of the advanced features box
(see Figure 3, bottom). In order to visually evaluate the departure from
constancy that the combined hazard ratio might have, CompARE depicts
the shape of the hazard ratio over time.
Discussion
The development of computational tools in biomedical research and clinical
trial studies is important to design more efficient trials. There exist several
software tools like EAST[21], nQuery[22], and PASS[23] that allows to cal-
culate sample sizes for specific endpoints, and therefore to study the most
efficient choice, but none includes the study of the efficiency of a composite
endpoint neither the calculation of the corresponding sample sizes whenever
the hazards are not proportional.
Our new web-based tool CompARE implements the ARE method and
allows to study the efficiency of each endpoint for different parameter value
combinations, even when the hazard ratio for the composite outcome is
time dependent. This tool performs complex computations based on the
ARE expression and it is crucial to facilitate the results to trialists without
programming skills.
CompARE is extended with new functionalities and features, and we
are constantly improving it thanks to the feedback of colleagues from differ-
ent universities, institutions and companies. For example, we are currently
implementing sample size calculations based on Freedman’s approach[24],
considering different accrual rates and including withdrawals. We are as
well working on extending CompARE to binary outcomes and to observa-
tional studies (Go´mez et al., 2016)[25].
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Conclusion
The free web-based platform CompARE is an exploratory tool that helps
trialists to make informed decisions on the primary endpoint of a clinical
trial. It allows to study how efficient might be a single endpoint versus a
combination of several outcomes. This decision would entail the option with
fewer numbers of patients in each treatment arm at the design stage of the
study. We remark that most of the cases, the hazard ratio of the composite
endpoint is not constant. With this computational resource, under some
assumptions, researchers can calculate sample sizes even when the propor-
tionality of the hazards’ assumption does not hold, and visually study its
departure over time.
CompARE performs the computations by means of a user-friendly graphic
interface, and no programming skills are required. Results are shown in writ-
ten form, detailed numerically with tables and depicted in plots for multiple
scenarios.
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Appendix
Computation of the Asymptotic Relative Efficiency (ARE)
Consider that the effect of treatment is to be evaluated on the time T
(j)
R to a
relevant event ER, where the superscript j indicates the treatment group (j = 0
for the control group and j = 1 for the treatment group). Assume now that an
additional endpoint EA is considered as a component of the primary endpoint and
that the composite endpoint E∗ = ER ∪ EA is to be used instead in order to prove
the efficacy of the new treatment. The effect of treatment would then be evaluated
on the time T
(j)
∗ to E∗, where T (j)∗ = min{T (j)R , T (j)A }, and T (j)A stands for the time
to EA for each group.
Let λ
(j)
k (t)(k = R,A) denote the marginal hazard for the relevant endpoint
(k = R) or the additional endpoint (k = A) when EA does not include a terminat-
ing event. Let λ
(j)
Ck(t)(k = R,A) denote the cause-specific hazard for the relevant
endpoint (k = R) or the additional endpoint (k = A) when EA includes a terminat-
ing event.
The relative treatment effects on ER and on EA are given by the hazard ra-
tios HRR(t) = λ˜
(1)
R (t)/λ˜
(0)
R (t) and HRA(t) = λ˜
(1)
A (t)/λ˜
(0)
A (t), respectively, where λ˜
stands indistinctly for λ or λCk, which we assume that they are constant over time.
That is, HRR(t) = HRR and HRA(t) = HRA. Let HR∗(t) denote the hazard
ratio for the composite endpoint.
Whenever the additional endpoint does not include a terminating event, the asymp-
totic relative efficiency ARE(Z∗, ZR) of the logrank test (Z∗) based on E∗ versus
the logrank test (ZR) based on ER is given by:
ARE(Z∗, ZR) =
(∫ 1
0
log
{
HR∗(t)f
(0)
∗ (t)dt
)2
(
log
{
HRR
})2
(
∫ 1
0
f
(0)
∗ (t)dt)(
∫ 1
0
f
(0)
R (t)dt)
,
and when the additional endpoint includes a terminating event,
ARE(Z∗, ZR) =
(∫ 1
0
log
{HRRλ(0)CR(t)+HRAλ(0)CA(t)
λ
(0)
CR(t)+λ
(0)
CA(t)
}
f
(0)
∗ (t)dt
)2
(log{HRR})2(
∫ 1
0
f
(0)
∗ (t)dt)V
,
being
V =
∫ 1
0
e−HRA
∫ t
0
λ
(0)
CA(u)duS
(0)
∗ (t)λ
(0)
CR(t)
e−
∫ t
0
λ
(0)
CA(u)dupi + e−HRA
∫ t
0
λ
(0)
CA(u)du(1− pi)
dt,
where f
(0)
R (t) and f
(0)
∗ (t) are the density functions of T
(0)
R and T
(0)
∗ , respectively;
S
(0)
∗ (t) stands for the survival function of T
(0)
∗ ; and pi stands for the null probability
of being in group 1. We refer to the original paper ([6]) for further details.
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